ArticleAllergy2013
A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy.
Article in Allergy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 131 citations in OpenAlex.
- Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity.The Journal of allergy and clinical immunology · 2020Trial
- Clinical Proteomics Applied to Food Allergy.Advances in experimental medicine and biology · 2026Review
- Article
- The Etiology of IgE-Mediated Food Allergy: Potential Therapeutics and Challenges.International journal of molecular sciences · 2025Review
- Self-Assembling Allergen Vaccine Platform Raises Therapeutic Allergen-Specific IgG Responses without Induction of Systemic Allergic Responses.ACS biomaterials science & engineering · 2024Article
- Treatment Approaches to Food Allergy.Handbook of experimental pharmacology · 2022Review
- New Insights in Therapy for Food Allergy.Foods (Basel, Switzerland) · 2021Review
- From Allergen Molecules to Molecular Immunotherapy of Nut Allergy: A Hard Nut to Crack.Frontiers in immunology · 2021Review
- Mouse Models of Food Allergy in the Pursuit of Novel Treatment Modalities.Frontiers in allergy · 2021Review
- Novel Approaches in the Inhibition of IgE-Induced Mast Cell Reactivity in Food Allergy.Frontiers in immunology · 2021Review
- Advances in Food Allergy Treatment.The Yale journal of biology and medicine · 2020Review
- [Recombinant allergens, peptides, and virus-like particles for allergy immunotherapy].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- Egg Allergy: Diagnosis and Immunotherapy.International journal of molecular sciences · 2020Review
- A proteomic analysis of peanut seed at different stages of underground development to understand the changes of seed proteins.PloS one · 2020Article
- Immunological Outcomes of Allergen-Specific Immunotherapy in Food Allergy.Frontiers in immunology · 2020Review
- Could This Be IT? Epicutaneous, Sublingual, and Subcutaneous Immunotherapy for the Treatment of Food Allergies.Current allergy and asthma reports · 2019Review
- Recombinant allergens for immunotherapy: state of the art.Current opinion in allergy and clinical immunology · 2019Review
- Novel vaccines: Technology and development.The Journal of allergy and clinical immunology · 2019Review
- Hypoallergenic Proteins for the Treatment of Food Allergy.Current allergy and asthma reports · 2019Review
- The Consortium for Food Allergy Research (CoFAR): The first generation.The Journal of allergy and clinical immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundImmunotherapy for peanut allergy may be limited by the risk of adverse reactions.
objectiveTo investigate the safety and immunologic effects of a vaccine containing modified peanut proteins.
methodsThis was a phase 1 trial of EMP-123, a rectally administered suspension of recombinant Ara h 1, Ara h 2, and Ara h 3, modified by amino acid substitutions at major IgE-binding epitopes, encapsulated in heat/phenol-killed E. coli. Five healthy adults were treated with 4 weekly escalating doses after which 10 peanut-allergic adults received weekly dose escalations over 10 weeks from 10 mcg to 3063 mcg, followed by three biweekly doses of 3063 mcg.
resultsThere were no significant adverse effects in the healthy volunteers. Of the 10 peanut-allergic subjects [4 with intermittent asthma, median peanut IgE 33.3 kUA /l (7.2-120.2), and median peanut skin prick test wheal 11.3 mm (6.5-18)]; four experienced no symptoms; one had mild rectal symptoms; and the remaining five experienced adverse reactions preventing completion of dosing. Two were categorized as mild, but the remaining three were more severe, including one moderate reaction and two anaphylactic reactions. Baseline peanut IgE was significantly higher in the five reactive subjects (median 82.4 vs 17.2 kUA /l, P = 0.032), as was baseline anti-Ara h 2 IgE (43.3 versus 8.3, P = 0.036). Peanut skin test titration and basophil activation (at a single dilution) were significantly reduced after treatment, but no significant changes were detected for total IgE, peanut IgE, or peanut IgG4.
conclusionsRectal administration of EMP-123 resulted in frequent adverse reactions, including severe allergic reactions in 20%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.